Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of CBC Group.

    Client Virtual Booth

    CBC GROUP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    CBC Group
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    2-15-13 Tsukishima, Chuo-ku, Tokyo 104-0052, Japan
    Telephone
    Telephone
    81 335 364 670
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.cbc.co.jp/en/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma

    Details:

    The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, used to treat hypertension.


    Lead Product(s): Azilsartan

    Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Hasten Biopharmaceutic

    Deal Size: $315.0 million Upfront Cash: Undisclosed

    Deal Type: Financing April 20, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Adcentrx Complete $50m Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & Development

    Details:

    Series A financing is raised to power the development of next generation ADC for improving patient treatment options.


    Lead Product(s): Antibody drug conjugate

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Recipient: Adcentrx Therapeutics

    Deal Size: $50.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing April 28, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    farmak-a-s-m-2024-08-26

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search